| _version_ |
1860796850924158976
|
| building |
INTELEK Repository
|
| collection |
Online Access
|
| collectionurl |
https://intelek.unisza.edu.my/intelek/pages/search.php?search=!collection407072
|
| date |
2013-09-14 02:12:04
|
| format |
Restricted Document
|
| id |
10420
|
| institution |
UniSZA
|
| internalnotes |
1. Rodríguez-Acebes S, Palacios N, Botella-Carretero JI, Olea N, Crespo L, Peromingo R, Gómez-Coronado D, Lasunción MA, Vázquez C, Martínez-Botas J: Gene expression profiling of subcutaneous adipose tissue in morbid obesity using a focused microarray: distinct expression of cell-cycle-and differentiation-related genes. BMC medical genomics 2010, 3:61. 2. Ibrahim MM: Subcutaneous and visceral adipose tissue: structural and functional differences. Obesity reviews 2010, 11:11-18. 3. Kershaw EE, Flier JS: Adipose tissue as an endocrine organ. Journal of Clinical Endocrinology & Metabolism 2004, 89:2548-2556. 4. Grundy SM, Brewer Jr HB, Cleeman JI, Smith Jr SC, Lenfant C: Definition of metabolic syndrome report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on scientific issues related to definition. Circulation 2004, 109:433-438. 5. Goossens GH: The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. Physiology & behavior 2008, 94:206-218. 6. Walczak R, Tontonoz P: PPARadigms and PPARadoxes: expanding roles for PPARγ in the control of lipid metabolism. Journal of lipid research 2002, 43:177-186. 7. Ferré P: The biology of peroxisome proliferator-activated receptors relationship with lipid metabolism and insulin sensitivity. Diabetes 2004, 53:S43-S50. 8. Desvergne B, Wahli W: Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocrine reviews 1999, 20:649-688. 9. Atlas of Genetics and Cytogenetics in Oncology and Haematology http://atlasgeneticsoncology.org/ 10. Ristow M, Müller-Wieland D, Pfeiffer A, Krone W, Kahn CR: Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. New England Journal of Medicine 1998, 339:953-959. 11. Meirhaeghe A, Fajas L, Helbecque N, Cottel D, Lebel P, Dallongeville J, Deeb S, Auwerx J, Amouyel P: A genetic polymorphism of the peroxisome proliferator-activated receptor γ gene influences plasma leptin levels in obese humans. Human Molecular Genetics 1998, 7:435-440. 12. Stumvoll M, Häring H: The peroxisome proliferator-activated receptor-γ2 Pro12Ala polymorphism. Diabetes 2002, 51:2341-2347. 13. Kliewer SA, Xu HE, Lambert MH, Willson TM: Peroxisome Proliferator-Activated Receptors From Genes to Physiology. Recent Progress in Hormone Research 2001, 56:239-265. 14. Gregoire FM, Smas CM, Sul HS: Understanding adipocyte differentiation. Physiological reviews 1998, 78:783-809. 15. Hwang C-S, Mandrup S, MacDougald OA, Geiman DE, Lane MD: Transcriptional activation of the mouse obese (ob) gene by CCAAT/enhancer binding protein alpha. Proceedings of the National Academy of Sciences 1996, 93:873-877. 16. Rosen ED, Spiegelman BM: PPARγ: a nuclear regulator of metabolism, differentiation, and cell growth. Journal of Biological Chemistry 2001, 276:37731-37734. 17. Schoonjans K, Peinado-Onsurbe J, Lefebvre A-M, Heyman RA, Briggs M, Deeb S, Staels B, Auwerx J: PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. The EMBO Journal 1996, 15:5336. 18. Tontonoz P, Hu E, Devine J, Beale EG, Spiegelman BM: PPAR gamma 2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene. Mol Cell Biol 1995, 15:351-357. 19. Olswang Y, Cohen H, Papo O, Cassuto H, Croniger CM, Hakimi P, Tilghman SM, Hanson RW, Reshef L: A mutation in the peroxisome proliferator-activated receptor γ-binding site in the gene for the cytosolic form of phosphoenolpyruvate carboxykinase reduces adipose tissue size and fat content in mice. Proceedings of the National Academy of Sciences 2002, 99:625-630. 20. Lefebvre A-M, Laville M, Vega N, Riou JP, van Gaal L, Auwerx J, Vidal H: Depot-specific differences in adipose tissue gene expression in lean and obese subjects. Diabetes 1998, 47:98-103. 21. Beamer BA, Yen C-J, Andersen RE, Muller D, Elahi D, Cheskin LJ, Andres R, Roth J, Shuldiner AR: Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor- 2 gene with obesity in two Caucasian populations. DIABETES-NEW YORK- 1998, 47:1806-1808. 22. Norman R, Thompson D, Foroud T, Garvey W, Bennett P, Bogardus C, Ravussin E: Genomewide search for genes influencing percent body fat in Pima Indians: suggestive linkage at chromosome 11q21-q22. Pima Diabetes Gene Group. American journal of human genetics 1997, 60:166. 23. Douglas JA, Erdos MR, Watanabe RM, Braun A, Johnston CL, Oeth P, Mohlke KL, Valle TT, Ehnholm C, Buchanan TA: The Peroxisome Poliferator–Activated Receptor-γ2 Pro12Ala Variant Association With Type 2 Diabetes and Trait Differences. Diabetes 2001, 50:886-890. 24. Lindi V, Sivenius K, Niskanen L, Laakso M, Uusitupa M: Effect of the Pro12Ala polymorphism of the PPAR-gamma2 gene on long-term weight change in Finnish non-diabetic subjects. Diabetologia 2001, 44:925. 25. Nicklas BJ, van Rossum EF, Berman DM, Ryan AS, Dennis KE, Shuldiner AR: Genetic variation in the peroxisome proliferator–activated receptor-γ2 gene (Pro12Ala) affects metabolic responses to weight loss and subsequent weight regain. Diabetes 2001, 50:2172-2176. 26. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J: A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998, 20:284-287. 27. Mori H, Ikegami H, Kawaguchi Y, Seino S, Yokoi N, Takeda J, Inoue I, Seino Y, Yasuda K, Hanafusa T: The Pro12→ Ala Substitution in PPAR-γ Is Associated With Resistance to Development of Diabetes in the General Population Possible Involvement in Impairment of Insulin Secretion in Individuals With Type 2 Diabetes. Diabetes 2001, 50:891-894.
|
| originalfilename |
4390-01-FH02-FPSK-14-00709.pdf
|
| person |
KSV
|
| recordtype |
oai_dc
|
| resourceurl |
https://intelek.unisza.edu.my/intelek/pages/view.php?ref=10420
|
| spelling |
10420 https://intelek.unisza.edu.my/intelek/pages/view.php?ref=10420 https://intelek.unisza.edu.my/intelek/pages/search.php?search=!collection407072 Restricted Document Article Journal application/pdf 4 1.6 Adobe Acrobat Pro DC 20 Paper Capture Plug-in KSV 2013-09-14 02:12:04 4390-01-FH02-FPSK-14-00709.pdf UniSZA Private Access Peroxisome Proliferactor Activated Receptor Gamma (PPAR-γ) Polymorphism Towards Obesity Endemic in Malaysia Vedic Research International Cell Signaling Obesity is pandemic and its associated co-morbidities, nowdays pose a major threat to global health systems. Obesity is often associated with adipose tissue dysfunction in which adiposity hypertrophy, adipose tissue hypo-perfusion and hypoxia, adipose tissue inflammation and macrophage infiltration are interrelated with each other in the pathophysiology and pathogenesis of obesity. Here we will discuss how genetic studies, through the discovery of peroxisome proliferactor-activated receptor gamma (PPAR-γ) have contributed to our understanding of the central pathways which govern the mechanism of how obesity develops in human. In Malaysia, we are still lacking information about the interaction of PPAR-γ polymorphism with obesity. We anticipate that future studies should emphasize more on genetic research, especially on lipid studies so that we could develop a most efficient and achievable targeted approach to the prevention and control of obesity accordingly. 1 1 7-10 1. Rodríguez-Acebes S, Palacios N, Botella-Carretero JI, Olea N, Crespo L, Peromingo R, Gómez-Coronado D, Lasunción MA, Vázquez C, Martínez-Botas J: Gene expression profiling of subcutaneous adipose tissue in morbid obesity using a focused microarray: distinct expression of cell-cycle-and differentiation-related genes. BMC medical genomics 2010, 3:61. 2. Ibrahim MM: Subcutaneous and visceral adipose tissue: structural and functional differences. Obesity reviews 2010, 11:11-18. 3. Kershaw EE, Flier JS: Adipose tissue as an endocrine organ. Journal of Clinical Endocrinology & Metabolism 2004, 89:2548-2556. 4. Grundy SM, Brewer Jr HB, Cleeman JI, Smith Jr SC, Lenfant C: Definition of metabolic syndrome report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on scientific issues related to definition. Circulation 2004, 109:433-438. 5. Goossens GH: The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. Physiology & behavior 2008, 94:206-218. 6. Walczak R, Tontonoz P: PPARadigms and PPARadoxes: expanding roles for PPARγ in the control of lipid metabolism. Journal of lipid research 2002, 43:177-186. 7. Ferré P: The biology of peroxisome proliferator-activated receptors relationship with lipid metabolism and insulin sensitivity. Diabetes 2004, 53:S43-S50. 8. Desvergne B, Wahli W: Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocrine reviews 1999, 20:649-688. 9. Atlas of Genetics and Cytogenetics in Oncology and Haematology http://atlasgeneticsoncology.org/ 10. Ristow M, Müller-Wieland D, Pfeiffer A, Krone W, Kahn CR: Obesity associated with a mutation in a genetic regulator of adipocyte differentiation. New England Journal of Medicine 1998, 339:953-959. 11. Meirhaeghe A, Fajas L, Helbecque N, Cottel D, Lebel P, Dallongeville J, Deeb S, Auwerx J, Amouyel P: A genetic polymorphism of the peroxisome proliferator-activated receptor γ gene influences plasma leptin levels in obese humans. Human Molecular Genetics 1998, 7:435-440. 12. Stumvoll M, Häring H: The peroxisome proliferator-activated receptor-γ2 Pro12Ala polymorphism. Diabetes 2002, 51:2341-2347. 13. Kliewer SA, Xu HE, Lambert MH, Willson TM: Peroxisome Proliferator-Activated Receptors From Genes to Physiology. Recent Progress in Hormone Research 2001, 56:239-265. 14. Gregoire FM, Smas CM, Sul HS: Understanding adipocyte differentiation. Physiological reviews 1998, 78:783-809. 15. Hwang C-S, Mandrup S, MacDougald OA, Geiman DE, Lane MD: Transcriptional activation of the mouse obese (ob) gene by CCAAT/enhancer binding protein alpha. Proceedings of the National Academy of Sciences 1996, 93:873-877. 16. Rosen ED, Spiegelman BM: PPARγ: a nuclear regulator of metabolism, differentiation, and cell growth. Journal of Biological Chemistry 2001, 276:37731-37734. 17. Schoonjans K, Peinado-Onsurbe J, Lefebvre A-M, Heyman RA, Briggs M, Deeb S, Staels B, Auwerx J: PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. The EMBO Journal 1996, 15:5336. 18. Tontonoz P, Hu E, Devine J, Beale EG, Spiegelman BM: PPAR gamma 2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene. Mol Cell Biol 1995, 15:351-357. 19. Olswang Y, Cohen H, Papo O, Cassuto H, Croniger CM, Hakimi P, Tilghman SM, Hanson RW, Reshef L: A mutation in the peroxisome proliferator-activated receptor γ-binding site in the gene for the cytosolic form of phosphoenolpyruvate carboxykinase reduces adipose tissue size and fat content in mice. Proceedings of the National Academy of Sciences 2002, 99:625-630. 20. Lefebvre A-M, Laville M, Vega N, Riou JP, van Gaal L, Auwerx J, Vidal H: Depot-specific differences in adipose tissue gene expression in lean and obese subjects. Diabetes 1998, 47:98-103. 21. Beamer BA, Yen C-J, Andersen RE, Muller D, Elahi D, Cheskin LJ, Andres R, Roth J, Shuldiner AR: Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor- 2 gene with obesity in two Caucasian populations. DIABETES-NEW YORK- 1998, 47:1806-1808. 22. Norman R, Thompson D, Foroud T, Garvey W, Bennett P, Bogardus C, Ravussin E: Genomewide search for genes influencing percent body fat in Pima Indians: suggestive linkage at chromosome 11q21-q22. Pima Diabetes Gene Group. American journal of human genetics 1997, 60:166. 23. Douglas JA, Erdos MR, Watanabe RM, Braun A, Johnston CL, Oeth P, Mohlke KL, Valle TT, Ehnholm C, Buchanan TA: The Peroxisome Poliferator–Activated Receptor-γ2 Pro12Ala Variant Association With Type 2 Diabetes and Trait Differences. Diabetes 2001, 50:886-890. 24. Lindi V, Sivenius K, Niskanen L, Laakso M, Uusitupa M: Effect of the Pro12Ala polymorphism of the PPAR-gamma2 gene on long-term weight change in Finnish non-diabetic subjects. Diabetologia 2001, 44:925. 25. Nicklas BJ, van Rossum EF, Berman DM, Ryan AS, Dennis KE, Shuldiner AR: Genetic variation in the peroxisome proliferator–activated receptor-γ2 gene (Pro12Ala) affects metabolic responses to weight loss and subsequent weight regain. Diabetes 2001, 50:2172-2176. 26. Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J: A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998, 20:284-287. 27. Mori H, Ikegami H, Kawaguchi Y, Seino S, Yokoi N, Takeda J, Inoue I, Seino Y, Yasuda K, Hanafusa T: The Pro12→ Ala Substitution in PPAR-γ Is Associated With Resistance to Development of Diabetes in the General Population Possible Involvement in Impairment of Insulin Secretion in Individuals With Type 2 Diabetes. Diabetes 2001, 50:891-894.
|
| spellingShingle |
Peroxisome Proliferactor Activated Receptor Gamma (PPAR-γ) Polymorphism Towards Obesity Endemic in Malaysia
|
| summary |
Obesity is pandemic and its associated co-morbidities, nowdays pose a major threat to global health systems. Obesity is often associated with adipose tissue dysfunction in which adiposity hypertrophy, adipose tissue hypo-perfusion and hypoxia, adipose tissue inflammation and macrophage infiltration are interrelated with each other in the pathophysiology and pathogenesis of obesity. Here we will discuss how genetic studies, through the discovery of peroxisome proliferactor-activated receptor gamma (PPAR-γ) have contributed to our understanding of the central pathways which govern the mechanism of how obesity develops in human. In Malaysia, we are still lacking information about the interaction of PPAR-γ polymorphism with obesity. We anticipate that future studies should emphasize more on genetic research, especially on lipid studies so that we could develop a most efficient and achievable targeted approach to the prevention and control of obesity accordingly.
|
| title |
Peroxisome Proliferactor Activated Receptor Gamma (PPAR-γ) Polymorphism Towards Obesity Endemic in Malaysia
|
| title_full |
Peroxisome Proliferactor Activated Receptor Gamma (PPAR-γ) Polymorphism Towards Obesity Endemic in Malaysia
|
| title_fullStr |
Peroxisome Proliferactor Activated Receptor Gamma (PPAR-γ) Polymorphism Towards Obesity Endemic in Malaysia
|
| title_full_unstemmed |
Peroxisome Proliferactor Activated Receptor Gamma (PPAR-γ) Polymorphism Towards Obesity Endemic in Malaysia
|
| title_short |
Peroxisome Proliferactor Activated Receptor Gamma (PPAR-γ) Polymorphism Towards Obesity Endemic in Malaysia
|
| title_sort |
peroxisome proliferactor activated receptor gamma (ppar-γ) polymorphism towards obesity endemic in malaysia
|